Mission of Kringle Pharma
PHILOSOPHY
We will contribute to our society and global health by research, development and commercialization of innovative medicines for patients suffering from incurable diseases.
Business Activities
OUR BUSINESS
Research and development of HGF protein medicines
Target indications
- Acute spinal cord injury
- Amyotrophic lateral sclerosis
- ALS Acute kidney injury
- Vocal fold scar
NEWS
- Dec 28, 2020Notice
-
Kringle Pharma, a late clinical-stage biopharmaceutical company developing recombinant human hepatocyte growth factor for incurable diseases such as acute spinal cord injury and ALS, announces the closing of its initial public offering on the Tokyo Stock Exchange Mothers market.
- Aug 31, 2020Notice
-
Kringle Pharma and Maruishi Pharmaceutical enter into a capital and business partnership for KP-100IT in acute spinal cord injury.
PDF
- Jul 20, 2020Notice
-
Kringle initiates Phase 3 clinical trial of recombinant human HGF for the treatment of acute spinal cord injury.
PDF
- Jun 19, 2020Notice
-
Kringle Pharma announces that positive clinical results from Phase I/II trial of recombinant human HGF, KP-100IT, in subjects with acute spinal cord injury were published in the peer-reviewed Journal of Neurotrauma (Published Online: 22 May 2020, DOI: 10.1089/neu.2019.6854).
- Apr 7, 2020Notice
-
Kringle Pharma additionally raises 740 million Japanese yen toward commercialization of recombinant human HGF drug.
PDF
- Mar 2, 2020Notice
-
Kringle Pharma successfully raises 950 million Japanese yen to advance clinical development of recombinant human HGF.
PDF
- Mar 2, 2020Notice
-
Kringle Pharma and Toho Holdings enter into a capital and business alliance for KP-100IT in acute spinal cord injury.
PDF
- Dec 26, 2019AGM
-
New board members were selected at the 18th general shareholders meeting, and the board members appointed Kiichi Adachi as President and CEO.
- Sep 23, 2019Notice
-
KP-100IT, recombinant human HGF for the treatment of acute spinal cord injury, was designated as an orphan drug in Japan as of September 12, 2019, with the approval of the Minister of Health, Labor and Welfare.
- Jan 7, 2019Notice
-
Phase I/II study of recombinant human HGF, KP-100IT, for acute spinal cord injury was completed, and the clinical study report has been issued. The positive results of this study will be published later in a scientific journal and presented at academic conferences.
- Jan 7, 2019Notice
-
Clinical data from Phase I study of recombinant human HGF, KP-100IT, for the treatment of ALS were published in Journal of Clinical Pharmacology (11 DEC 2018, DOI: 10.1002/jcph.1355). It was indicated that intrathecal administration of KP-100IT was safe and tolerable. Following the Phase I study, an investigator-initiated Phase II study is currently underway to confirm therapeutic efficacy of KP-100IT against ALS.
- Dec 21, 2018AGM
-
New board members were selected at the 17th general shareholders meeting, and the board members appointed Kiichi Adachi as President and CEO.
- Jul 31, 2018Notice
-
Kringle Pharma successfully raised 200 million JPY in funding from THVP-1 Fund (General Partner: Tohoku University Venture Partners Co., Ltd.).
- Jun 1, 2018Notice
-
Kringle’s recombinant human HGF is now available as a research reagent at REPROCELL, Inc. For more information, please contact REPROCELL, Inc. through their website as follows. https://www.reprocell.com/
- May 11, 2018Notice
-
Kringle Pharma announces that the last subject has completed the follow-up period after dosing in the Phase I/II study of recombinant human HGF for acute spinal cord injury.